Skip to main content

Table 3 Pharmacokinetics of scFv(FRP5)-ETA

From: Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Dose level (μg/kg) Peak concentration range (ng/ml) Peak concentration mean (ng/ml) AUC (ng* hour/ml) Plasma clearance (l/hour) Half-life (hours)
2 n.d. n.d. n.d. n.d. n.d.
4 18–49 39 ± 18 39 ± 1 6.6 ± 0.6 0.55 ± 0.02
10 128–129 129 ± 1 138 ± 64 5.3 ± 2.1 0.74 ± 0.27
12.5 93–204 160 ± 35 178 ± 100 4.9 ± 3.1 0.73 ± 0.30
20 115–307 236 ± 105 326 ± 146 3.8 ± 2.2 0.73 ± 0.22
  1. AUC, area under the concentration–time curve; n.d., not determined.